We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




AI Technology Accurately Predicts Breast Cancer Risk Via ‘Zombie Cells’

By LabMedica International staff writers
Posted on 30 Sep 2024

Breast cancer remains one of the most common cancers worldwide, causing 670,000 deaths in 2022. More...

A key aspect of assessing cancer risk involves identifying dying cells. A new study has demonstrated that artificial intelligence (AI) can enhance treatment for women by identifying irregular-looking cells, thus improving cancer risk assessment. The study, published in The Lancet Digital Health, found that AI significantly outperformed current clinical benchmarks for breast cancer risk prediction.

Researchers from the University of Copenhagen (Copenhagen, Denmark) used deep learning AI technology to analyze mammary tissue biopsies from donors, searching for signs of cell damage, a marker of cancer risk. This damage is linked to cellular senescence, where cells stop dividing but remain metabolically active. While senescent cells can help suppress cancer development, they can also trigger inflammation, which may lead to tumor formation. By using AI to detect these senescent cells in tissue samples, the researchers were able to predict breast cancer risk more effectively than the Gail model, the current standard for risk assessment.

To train the AI, the researchers used cells in a lab that were intentionally damaged to induce senescence. The AI was then applied to donor biopsies to detect senescent cells—often called "zombie cells" because they have lost some functions but are not entirely dead. These cells are closely associated with cancer development, so the AI algorithm was designed to predict senescence by analyzing the irregular shapes of cell nuclei, which change as the cells become senescent. The study also found that combining two AI models or integrating an AI model with the Gail score, greatly improved cancer risk predictions. One combination produced an odds ratio of 4.70, indicating that donors with certain cell features had nearly five times the risk of developing cancer in the coming years. While it will take time before this technology is available in clinical settings, its potential is global. Since the method only requires standard tissue sample images, it could eventually be used worldwide, offering women better insights for treatment decisions.

“The algorithm is a great leap forward in our ability to identify these cells. Millions of biopsies are taken every year, and this technology can help us better identify risks and give women better treatment,” said Associate Professor Morten Scheibye-Knudsen from the Department of Cellular and Molecular Medicine and senior author of the study. “We will be able use this information to stratify patients by risk and improve treatment and screening protocols. Doctors can keep a closer eye on high-risk individuals, they can undergo more frequent mammograms and biopsies, and we can potentially catch cancer earlier. At the same time, we can reduce the burden for low-risk individuals, e.g. by taking biopsies less frequently.”

Related Links:
University of Copenhagen


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Acute lymphoblastic leukemia in children and young people requires careful relapse risk assessment as treatment expands beyond standard chemotherapy. (Image Credit: Shutterstock)

New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL

Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Technology

view channel
Image: Diatech Pharmacogenetics launches Labcycler, a compact PCR thermal cycler. (Photo courtesy of Diatech Pharmacogenetics)

Compact PCR Thermal Cycler Launches for Routine Molecular Laboratory Workflows

Molecular laboratories rely on nucleic acid analysis to detect molecular information accurately and reproducibly across a wide range of applications. Supporting these routine workflows, a newly launched... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.